Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM et al (2019) Acromegaly Nat Rev Dis Primers 5(1):20

Article  PubMed  Google Scholar 

Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G et al (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43(6):1003–1037

Article  PubMed  PubMed Central  Google Scholar 

Giustina A, Boni E, Romanelli G, Grassi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75(15):1042–1047

Article  CAS  PubMed  Google Scholar 

Giustina A (2023) Acromegaly and bone: an update. Endocrinol Metab (Seoul) 38(6):655–666

Article  PubMed  Google Scholar 

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al (2020) A Consensus on the diagnosis and treatment of Acromegaly comorbidities: an update. J Clin Endocrinol Metab. 105(4)

Giustina A (2016) [Acromegaly: reducing diagnostic delay]. Recenti Prog Med 107(8):450–451

PubMed  Google Scholar 

Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182(6):523–531

Article  CAS  PubMed  Google Scholar 

Chiloiro S, Giampietro A, Gagliardi I, Bondanelli M, Veleno M, Ambrosio MR et al (2022) Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 1–11

Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of Acromegaly and the impact of the Current Treatment Landscape: an update. Endocr Rev 40(1):268–332

Article  PubMed  Google Scholar 

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667–678

Article  PubMed  PubMed Central  Google Scholar 

Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7–22

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH et al (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561

Article  PubMed  PubMed Central  Google Scholar 

Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N et al (2015) Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 100(4):1699–1708

Article  CAS  PubMed  Google Scholar 

Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1–13

Article  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2023) 9. Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes-2023. Diabetes Care 46(Suppl 1):S140–s57

Article  CAS  PubMed  Google Scholar 

Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS et al (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement. Pituitary 20(5):489–498

Article  PubMed  PubMed Central  Google Scholar 

Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF (2020) Pituitary Tumors Centers of Excellence. Endocrinol Metab Clin North Am 49(3):553–564

Article  PubMed  Google Scholar 

Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P et al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26(5):583–596

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giustina A, Karamouzis I, Patelli I, Mazziotti G (2013) Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother 14(17):2433–2447

Article  CAS  PubMed  Google Scholar 

Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) The Modern Criteria for Medical Management of Acromegaly. Prog Mol Biol Transl Sci 138:63–83

Article  PubMed  Google Scholar 

Marazuela M, Ramos-Leví A, Sampedro-Núñez M, Bernabeu I (2014) Cabergoline treatment in acromegaly: pros. Endocrine 46(2):215–219

Article  CAS  PubMed  Google Scholar 

Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L et al (2017) Pegvisomant in acromegaly: an update. J Endocrinol Invest 40(6):577–589

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875–884

Article  CAS  PubMed  Google Scholar 

van der Lely AJ, Kuhn E, Muhammad A, Coopmans EC, Neggers SJ, Chanson P (2020) Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly. Eur J Endocrinol 182(6):D17–d29

Article  PubMed  Google Scholar 

Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80(2):303–307

Article  CAS  PubMed  Google Scholar 

Urwyler SA, Samperi I, Lithgow K, Mavilakandy A, Matheou M, Bradley K et al (2024) Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. Eur J Endocrinol

Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes Mellitus in Acromegaly. Trends Endocrinol Metab 27(7):470–483

Article  CAS  PubMed  Google Scholar 

Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, Fleseriu CM et al (2021) Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73(3):658–666

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ et al (2018) Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179(6):419–427

Article  CAS  PubMed  Google Scholar 

Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J et al (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185(4):525–538

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK et al (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125–133

Article  CAS  PubMed  Google Scholar 

Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S (2020) Cost-effectiveness and efficacy of a Novel Combination Regimen in Acromegaly: a prospective, randomized trial. J Clin Endocrinol Metab. 105(9)

Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99(5):1825–1833

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR (2016) Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19(3):235–247

Article  CAS  PubMed  Google Scholar 

Giustina A, Mazziotti G, Cannavò S, Castello R, Arnaldi G, Bugari G et al (2017) High-dose and High-Frequency Lanreotide Autogel in Acromegaly: a Randomized, Multicenter Study. J Clin Endocrinol Metab 102(7):2454–2464

Article  PubMed  Google Scholar 

Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S et al (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161(2):331–338

Article  CAS  PubMed  Google Scholar 

Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C et al (2021) International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. J Clin Endocrinol Metab 106(12):3555–3568

PubMed  Google Scholar 

Giustina A, Bevan J, Bronstein M, Casanueva F, Chanson P, Petersenn S et al (2014) Sagit©: a novel clinician-reported outcome for managing Acromegaly in Clinical Practice. Value Health 17(7):A355

Article  CAS  PubMed  Google Scholar 

Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L et al (2019) Pasireotide and Pegvisomant Combination Treatment in Acromegaly resistant to second-line therapies: a longitudinal study. J Clin Endocrinol Metab 104(11):5478–5482

Article  PubMed  Google Scholar 

Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA et al (2014) Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 99(10):3644–3652

Article  CAS  PubMed  Google Scholar 

Trainer PJ, Ezzat S, D’Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71(4):549–557

Article